Related Experiment Video
Updated: Oct 18, 2025
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
Sayeh Saravi1, Zena Alizzi1,2, Sabrina Tosi1
1Division of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK.
Background:
Approximately 50% of ovarian cancer patients harbour homologous recombination repair deficiencies. These deficiencies have been successfully targeted using poly (ADP-ribose) polymerase inhibitors (PARPi) particularly for patients harbouring BRCA1/2 mutations. The aim of this study is to assess the effects of the PARPi rucaparib in vitro using cell lines with BRCA2 mutations in comparison to those with BRCA2 wild type.
Methods:
Cell proliferation assays, RT-qPCR, immunofluorescence, annexin V/PI assays were used to assess the effects of rucaparib in vitro.
Results:
The BRCA2 mutant ovarian cancer cell line PEO1 exhibited higher PARP1 activity when treated with H2O2 compared to wild type cell lines. The migratory and proliferative capacity of PEO1 cells was compromised following treatment with rucaparib 10 µM compared to BRCA2 wild-type cell lines via a mechanism involving the mTOR pathway. Rucaparib treatment significantly increased DNA damage primarily in PEO1 cells and SKOV3 cells compared with wild type.
Conclusions:
Appropriate identification of robust predictive biomarkers for homologous recombination deficiency using 'liquid' biopsies would facilitate the identification of patients suitable for PARPi therapy. Preliminary efforts to undertake such testing are described here. This study also demonstrates the mechanisms of action of rucaparib (PARPi) which may involve elements of the mTOR pathway.
Insights
Rucaparib effectively reduced ovarian cancer cell migration and proliferation in BRCA2-mutant cells, demonstrating its potential as a targeted therapy. This poly (ADP-ribose) polymerase inhibitor (PARPi) also induced DNA damage, highlighting its mechanism of action.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer often presents with homologous recombination repair deficiencies, affecting approximately 50% of patients.
- Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective treatments for ovarian cancer patients with BRCA1/2 mutations.
- Targeting homologous recombination repair deficiencies offers a promising therapeutic strategy in ovarian cancer.
Purpose of the Study:
- To evaluate the in vitro effects of the PARPi rucaparib on ovarian cancer cell lines.
- To compare the efficacy of rucaparib in cell lines with BRCA2 mutations versus BRCA2 wild-type.
- To investigate the mechanisms underlying rucaparib's action in ovarian cancer.
Main Methods:
- Cell proliferation assays were employed to measure cell growth.
- Quantitative real-time PCR (RT-qPCR) assessed gene expression.
- Immunofluorescence and Annexin V/Propidium Iodide (PI) staining evaluated cellular effects and apoptosis.
Main Results:
- BRCA2-mutant PEO1 cells showed increased PARP1 activity after H2O2 treatment compared to wild-type cells.
- Rucaparib (10 µM) significantly inhibited PEO1 cell migration and proliferation, involving the mTOR pathway.
- Rucaparib treatment led to increased DNA damage in PEO1 and SKOV3 cells compared to wild-type controls.
Conclusions:
- Rucaparib demonstrates anti-cancer effects in BRCA2-mutant ovarian cancer cells by inhibiting proliferation and migration.
- The mTOR pathway may be involved in rucaparib's mechanism of action.
- Developing predictive biomarkers for homologous recombination deficiency is crucial for patient selection in PARPi therapy.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:21Cancer Survival Analysis
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...